Acura Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Acura Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of deterrents to medication abuse and misuse. As of 2012, the company had several principal opioid products under development, which would utilized "Aversion Technology".[1] As of 2014, the company was a publicly traded company, listed on NASDAQ under the symbol "ACUR".

Acura Pharmaceuticals Inc.
Type Public
Traded as NASDAQ:ACUR
Industry Pharmaceutical Industry
Founded 1935[general 1]:3
Headquarters United States
Products Pharmaceutics
Website acurapharm.com

History[edit]

In 2013, the Company settled Oxecta patent litigation with Impax Laboratories (IPXL) and Par Pharmaceutical.[2]

Technologies[edit]

Aversion Technology[edit]

Aversion Technology, patented by Acura, provides abuse deterrent benefits to orally administered pharmaceutical drugs.[3][4] Many of the products approved by the US Food and Drug Administration, such as OXECTA from Pfizer, have incorporated such technology.[citation needed]

Impede Technology[edit]

Impede Technology is used in easily dissolved tablets and involves the addition of an inactive ingredent polymer matrix, which has been shown to form a thick gel and start a conversion process of crushed pseudoephedrine (PSE).[5] This technology the aims of the Combat Methamphetamine Epidemic Act enacted in the United States in 2006.[6]

Corporate Affairs[edit]

License Agreements[edit]

The company has an agreement to license, develop and commercialize opioid analgesic products with King Pharmaceuticals.[7]

Product Adoptions[edit]

In 2013, Kroger stocked Acura's product Nexafed, which is an abuse-deterrent meth-resistant drug that incorporated the new pseudoephedrine conversion technology from the company.[8]

References[edit]

  1. ^ "Acura Pharmaceuticals, Inc.". Google Finance. Google. 266634. Retrieved February 15, 2014. 
  2. ^ "Acura Pharmaceuticals Inc Announces Settlement of Oxecta Patent Litigation With Par Pharmaceutical and Impax Laboratories Inc". Reuters. Reuters. October 9, 2013. Archived from the original on February 15, 2014. 
  3. ^ "Acura Pharmaceuticals, Inc. (ACUR) Announces Termination of AVERSION License Agreement With Pfizer Inc. (PFE)". BioSpace. Dice Holdings. September 27, 2012. Archived from the original on November 8, 2012. Retrieved February 15, 2014. 
  4. ^ "Acura Pharmaceuticals Announces Earlier Return of Development Products" (Press release). Acura Pharmaceuticals. September 26, 2012. Archived from the original on December 16, 2012. Retrieved February 15, 2014. 
  5. ^ "How Impede Technology Works". Nexafed. Acura Pharmaceuticals. Archived from the original on February 15, 2014. Retrieved February 15, 2014. 
  6. ^ "IMPEDE® Technology". Acura Pharmaceuticals. Archived from the original on December 18, 2013. Retrieved February 15, 2014. 
  7. ^ http://finance.yahoo.com/q/pr?s=ACUR+Profile
  8. ^ Olsavsky, Rebecca (February 4, 2014). "Kroger stocks meth-resistant drug". Herald-Star. Archived from the original on February 15, 2014. Retrieved February 15, 2014. 

General references[edit]

  1. ^ "ACURA PHARMACEUTICALS, INC" (PDF). EDGAR Online. Form 10-K, 1996. Acura Pharmaceuticals. March 31, 1997. Retrieved February 15, 2014.